Thanks to our CAH community for your participation in our recent survey. Based on your feedback, we are working to update our site to better serve your needs.

We are listening, continue to speak up.  CAHmelia@sprucebiosciences.com

The CAHmelia program is dedicated to exploring solutions for the symptoms that matter most to you.

Through the CAHmelia trials. Spruce Biosciences is evaluating once-daily tildacerfont, a new investigational drug that seeks to shift the treatment paradigm for congenital adrenal hyperplasia (CAH). Tildacerfont is NOT a steroid. The primary purpose of the CAHmelia program is to assess if  tildacerfont is effective in lowering androgens (testosterone related hormones) and daily glucocorticoid  doses in patients with classic CAH.

For more information on the ongoing trials in adult patients with classic CAH, please visit:

TOGETHER, WE CAN EXPLORE A BRIGHTER FUTURE FOR GENERATIONS LIVING WITH CLASSIC CAH